When it comes to reaching our career goals, we can often be our own worst enemy. We can blame others for standing in the way, but the truth is many of our own common habits are preventing us from reaching our objectives. Consider these three ways you are sabotaging your own success.You’re procrastinating“There’s always tomorrow.” We all have said this phrase at one point or another, but the fact is that none of us know what tomorrow will bring. Something unexpected may come up that will prevent us from getting done what we didn’t accomplish the day before. The longer we put things off, the harder it is to actually buckle down and cross tasks off the list. You are the only one that can control the pace in which you work and the amount you choose to get done.You’re scared of taking risksWho doesn’t love staying in their comfort zone? It’s a scary thing to step outside the box and try something new. Most of us love that feeling of knowing what we can expect and playing it safe. But, until you make that leap and take risks, you may never reach your full potential.You’re afraid of successAlthough we look forward to the idea of accomplishing what we set out to do, many of us fear what will happen when we get there. Once you reach that level of success, a lot more will likely be expected of you, and that’s a frightening thought. Running with the pack is comfortable, but once you push forward and stand out on your own, all eyes are on you. Ask yourself, “Do I really want to reach my goal,” and if the answer is truly yes, then it’s time to look ahead and stop standing in your own way. 27SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr,Wendy Moody Wendy Moody is a Senior Editor with CUInsight.com. Wendy works with the editorial team to help edit the content including current news, press releases, jobs and events. She keeps … Web: www.cuinsight.com Details
The USC women’s cross country team has spent much of the season trying to recover from the flu and injury.The week when all of the Women of Troy’s top runners are finally healthy could not have come at a better time.“From the beginning of August until the end of last week, we had someone sick or hurt every single week,” said USC coach Tom Walsh. “I’m glad it’s behind us now.”Finally armed with what Walsh believes are its strongest nine runners, USC will host the Pac-10 Conference Championships for the first time since 1999 on Friday at Skylinks Golf Course in Long Beach, Calif. And although USC will face daunting competition, Walsh believes the home-course advantage will benefit the team.“Since we’re hosting it, we got to put the course together,” he said. “It will be a very flat, very fast course. I think we’ll do really well on it.”The Pac-10 features four nationally ranked women’s squads: No. 17 Arizona, No. 12 Stanford, No. 8 Oregon and No. 1 Washington. With the incredible quality of competition at the meet, Walsh’s expectations are realistic.“I want to be really competitive,” he said. “It’s a stretch for us to be in the top five. But if we can be as competitive as possible and beat our rival UCLA and finish somewhere in the middle of the pack, then that would be an outstanding performance by these girls.”The Women of Troy include a few standouts, like junior Zsofia Erdelyi, as well as a few surprise runners, like junior Dina Kitayama, who used strong October surges to vault into contention for USC’s Pac-10 squad. Walsh said choosing the runners who would fill out the last few roster spots proved to be a difficult decision.“There were five people competing for the last two spots who I could have realistically chosen,” Walsh said. “I went with my gut and who I think will respond to pressure and run the best on that day.”Rounding out USC’s team are senior captain Bridget Helgerson, junior Christine Cortez, senior Katherine Ellis, junior Zara Lukens, sophomore Leah Gaeta, and freshmen Kathleen Moloney and Kelly Owen. Walsh said all nine girls have had strong practices in the weeks leading up to Friday’s meet.“It reminds me of last year,” Walsh said. “This time last year is when we really started to practice well and ended up having a breakout race [at Bakersfield]. We’ve had those types of practices leading up to this meet, so I’m hoping it carries over.”The Pac-10 men’s and women’s Cross Country Championships will be Friday, with the men running at 3 p.m., and the women at 4 p.m.
Anand Anandkumar’s father was a physician who spent his career fighting infectious diseases in the South Indian city of Chennai. It was an infection that killed him.In and out of hospital for a failing heart, he picked up a bug resistant to most antibiotics and died of complications from sepsis.His story is common in India, where so-called superbugs kill nearly 60,000 newborns every year. The rapid spread of resistant bacteria has made India the epicenter of a war to prevent a post-antibiotic world, where people would once again die in the thousands of commonplace infections.“We’re on the front line,” said Anandkumar, who a year after his father’s death co-founded Bengaluru-based startup Bugworks Research India, to develop new antibiotics. “We’re creating a bullet against organisms that are taking out humanity. Wouldn’t it be nice to get a battleground to test it on that’s really tough?”Anand Anandkumar, chief executive officer and managing director of Bug Works, during an interview in Bengaluru, India, on May 31, 2018. Photo Credit: : Samyukta Lakshmi/BloombergThe theater of war is all around him. India has few weapons to fight infection after years of poorly controlled antibiotic use in humans and animals, combined with effluent from the local drug industry that turned lakes and streams into breeding grounds for resistance. A study of one hospital in South India found half the patients acquired at least one infection during their stay, with about 74 percent of those infections showing resistance to multiple drugs.The Indian government has begun to provide early research funding, advice and support to startups like Bugworks. It also funds the startup incubator that Bugworks shares with 21 other biotech firms.Last year, Bugworks became the first company in Asia to receive investment from CARB-X, the U.S. government’s main funding vehicle for the fight against superbugs.“The science is as good as anywhere else,” said Ramanan Laxminarayan, a professor at Princeton University and director of the Center for Disease Dynamics, Economics & Policy, based in Washington and New Delhi. “On a per dollar basis, I think the chance of a new antibiotic discovery is as great or higher in India as anywhere.”Governments have begun to take concerted action in the last few years. In 2015 the U.S. launched its Combating Antibiotic Resistant Bacteria initiative. The next year the British government commissioned a report that found superbugs kill about 700,000 people around the world each year, a figure that could rise to 10 million a year by 2050 if nothing is done.Bugworks’ answer is an antibiotic that attacks bacteria in two ways at once rather than the single target approach of traditional drugs, making it harder for the bug to develop resistance. The drug also evades the bacteria’s own defenses, giving it more time to kill the infection.Anandkumar says the compound has shown effectiveness against lung, blood and urinary tract infections in animals. In about two years, he says, it should be ready for human trials.T.S. Balganesh in Bangalore, India, on May 30, 2018. Photo Credit: Samyukta Lakshmi/BloombergIndia’s low research costs and deep pool of biotech graduates mean Bugworks isn’t alone in trying to stem the superbug tide. In the same building, Biomoneta is focusing on an air purification system that kills bacteria in hospitals before they can infect patients.In a nearby industrial zone is GangaGen Inc., named in honor of the founder’s mother, who was killed by an infection. The startup is working with bacteria-eating viruses called phages to isolate proteins that can make superbug-killing drugs. It has developed a drug that targets staph infections and is seeking more drugs that treat other infections using the same method.Other companies from the nearby city of Hyderabad and the capital, New Delhi, have joined the fight.“You’re probably sitting in the epicenter of the problem,” said Janani Venkatraman, Biomoneta’s founder. “But there are also so many people working to solve the problem, and that makes for an extremely exciting and collaborative ecosystem.”But turning the ideas into safe, available drugs requires a lot of money and expertise in human testing and approvals. And that means enlisting the big pharmaceutical companies that haven’t brought a new antibiotic to market for 30 years.Janani Venkatraman, founder anddDirector of Biomoneta, in Bangalore, India, on June 1, 2018. Photo Credit: Samyukta Lakshmi/BloombergInvesting in treatments for diseases that last a lifetime, like diabetes or hypertension, was better business than a drug the patient takes once. And increasing regulation of antibiotics by governments that might insist any new treatment be used only as a last resort, make it even less financially attractive.Nevertheless, the tide is turning. More than 80 health-care companies, including Pfizer, Novartis and GlaxoSmithKline, pledged to help fight antimicrobial resistance at the World Economic Forum in 2016. Governments are providing subsidies, fast-tracking approvals and extending patent protection.The big pharmaceutical companies are also slowly bringing their antibiotic research pipelines back to life, led by U.K.-based Glaxo. Pfizer announced a program earlier this year with the Indian Council of Medical Research.In the meantime, the fight revolves around efforts to slow the development of resistance by tightening rules on how antibiotics are dispensed, especially in livestock farming, where widespread misuse of the drugs has been one of the biggest contributors to the rise of superbugs.One thing that drives the effort in India is the personal experience of so many researchers. Staff at Bugworks recount stories of friends in their forties dying in hospital from pneumonia, or from a urinary tract infection that lasts months as one antibiotic after another fails to work.T.S. Balganesh, president of GangaGen, tells of the wife of a close friend who went to hospital for a stomach operation and died of pneumonia within a fortnight, and an aunt who went in to treat a burn and died from an infection a week later.“Friends go to hospital and don’t come back,” he said.(c) 2018, Bloomberg Related ItemsStartup